Skip to main content

Table 3 Clinical characteristics in the two subgroups of prefibrotic and fibrotic PMF

From: Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis

 

Prefibrotic PMF

Fibrotic PMF

p value

Sex

M:F = 11/15

M:F = 15/31

n.s.

Median age at diagnosis (years)

43 (20–87)

61 (27–83)

p = 0.019

WBC at diagnosis (109/l)

9100

8745

n.s.

Hb at diagnosis (g/dl)

14.6

14.3

n.s.

PLT at diagnosis (109/l)

825000

797500

n.s.

Increased LDH

6/19 (31.6%)

19/31 (61.3%)

n.s.

Splenomegaly (%)

6 (23%)

12 (26%)

n.s.

JAK2V617-positive (%)

9 (50%)

14 (58%)

n.s.

History of thrombosis (%)

6 (23%)

10 (22%)

n.s.

Thrombosis at diagnosis (%)

4 (15%)

7 (15%)

n.s.

Thrombotic events during follow-up (%)

6 (23%)

5 (10%)

n.s.

Progression to overt MF (%)

0 (0%)

3 (6.5%)

n.s.

Dead/Alive

2/24

6/40

n.s.

Conventional Risk (Low/High)

13/13

17/29

n.s.

Cytoreductive therapy (%)

24 (92%)

40 (86%)

n.s.